A Phase 3 interventional study of Cariprazine and Aripiprazole in Schizophrenia, sponsored by Forest Laboratories. Completed at 58 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-10-29.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 5th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 3 started in 2010.
This study's enrollment of 617 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
27 studies in Schizophrenia by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 5th largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 3, and was the 8th registered.
AbbVie’s Schizophrenia studies by the year they started, since 2004.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Drug: Cariprazine
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Drug: Cariprazine
Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Drug: Aripiprazole
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Drug: Placebo
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Also known as: RGH-188
Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.
The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change from baseline score indicates improvement.
Time frame: Baseline to Week 6
Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)
The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change from baseline score indicates improvement.
Time frame: Baseline to Week 6
| Milestone | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg |
|---|---|---|---|---|
| Started | 153 | 155 | 157 | 152 |
| Completed | 95 | 104 | 97 | 114 |
| Not completed | 58 | 51 | 60 | 38 |
| Withdrew: Did not meet inc/exc criteria | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 17 | 15 | 20 | 14 |
| Withdrew: Lack of efficacy | 20 | 15 | 14 | 8 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 19 | 25 | 15 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 1 |
The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change from baseline score indicates improvement.
| Units on a Scale | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg |
|---|---|---|---|---|
| Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. | -14.3 ± 1.5 | -20.2 ± 1.5 | -23.0 ± 1.5 | -21.2 ± 1.4 |
The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change from baseline score indicates improvement.
| Units on a Scale | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg |
|---|---|---|---|---|
| Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S) | -1.0 ± 0.1 | -1.4 ± 0.1 | -1.5 ± 0.1 | -1.4 ± 0.1 |
Collected over Assessed over 2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/153 (0%) | 2/153 (1.3%) | 68/153 (44.4%) |
| Cariprazine 3.0 mg | 0/155 (0%) | 4/155 (2.6%) | 61/155 (39.4%) |
| Cariprazine 6.0mg | 2/157 (1.3%) | 7/157 (4.5%) | 71/157 (45.2%) |
| Aripiprazole 10.0 mg | 0/152 (0%) | 4/152 (2.6%) | 61/152 (40.1%) |
| Event | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg |
|---|---|---|---|---|
| Psychotic disorderPsychiatric disorders | 0/153 | 2/155 | 0/157 | 0/152 |
| Social stay hospitalizationSurgical and medical procedures | 0/153 | 0/155 | 1/157 | 1/152 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 0/153 | 0/155 | 0/157 | 1/152 |
| DepressionPsychiatric disorders | 0/153 | 0/155 | 0/157 | 1/152 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/153 | 0/155 | 0/157 | 1/152 |
| Artropod biteInjury, poisoning and procedural complications | 1/153 | 0/155 | 0/157 | 0/152 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/153 | 0/155 | 0/157 | 0/152 |
| Schizophrenia, paranoid typePsychiatric disorders | 0/153 | 1/155 | 1/157 | 0/152 |
| SchizophreniaPsychiatric disorders | 0/153 | 1/155 | 0/157 | 0/152 |
| Supraventricular tachycardiaCardiac disorders | 0/153 | 1/155 | 0/157 | 0/152 |
| Event | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 25/153 | 21/155 | 22/157 | 16/152 |
| AkathisiaNervous system disorders | 9/153 | 12/155 | 24/157 | 11/152 |
| HeadacheNervous system disorders | 17/153 | 10/155 | 16/157 | 15/152 |
| AnxietyPsychiatric disorders | 11/153 | 12/155 | 12/157 | 12/152 |
| AgitationPsychiatric disorders | 12/153 | 3/155 | 4/157 | 8/152 |
| SchizophreniaPsychiatric disorders | 12/153 | 3/155 | 4/157 | 8/152 |
| NauseaGastrointestinal disorders | 5/153 | 3/155 | 5/157 | 11/152 |
| Abdominal discomfortGastrointestinal disorders | 3/153 | 1/155 | 7/157 | 9/152 |
| Vaginal InfectionInfections and infestations | 0/56 | 3/56 | 0/57 | 0/58 |
The randomized population is also the safety population.
| Age, Continuous(Years) | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.2 ± 11.3 | 37.9 ± 10.6 | 38.6 ± 10.6 | 39.3 ± 10.8 | 38.5 ± 10.8 |
| Sex/Gender, Customized(Participants) | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg | Total |
|---|---|---|---|---|---|
| Male | 97 | 99 | 100 | 94 | 390 |
| Female | 56 | 56 | 57 | 58 | 227 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 | 2 | 12 |
| Not Hispanic or Latino | 137 | 134 | 133 | 134 | 538 |
| Unknown or Not Reported | 13 | 19 | 19 | 16 | 67 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine 3.0 mg | Cariprazine 6.0mg | Aripiprazole 10.0 mg | Total |
|---|---|---|---|---|---|
| White | 93 | 102 | 101 | 99 | 395 |
| Black or African-American | 42 | 32 | 36 | 33 | 143 |
| Asian | 1 | 1 | 0 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 0 | 1 | 5 |
| Other | 2 | 2 | 3 | 1 | 8 |
| Missing | 12 | 17 | 17 | 16 | 62 |
Ran from Apr 2010 to primary completion in Dec 2011, 19 months.
Results were first posted in Oct 2018, 6 years 10 months after primary completion. A results delay was requested in Dec 2011.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 19 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine